- Home
- GERN vs CSAN Comparison
GERN vs CSAN Comparison
Compare GERN & CSAN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GERN | CSAN |
|---|---|---|
| Founded | 1990 | 1936 |
| Country | United States | Brazil |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Retail-Auto Dealers and Gas Stations |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 753.3M | 4.0B |
| IPO Year | 1996 | N/A |
Fundamental Metrics
Financial Performance| Metric | GERN | CSAN |
|---|---|---|
| Price | $1.32 | $3.97 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 3 |
| Target Price | $3.00 | ★ $9.50 |
| AVG Volume (30 Days) | ★ 6.8M | 2.0M |
| Earning Date | 11-05-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $183,403,000.00 | ★ $7,988,294,917.00 |
| Revenue This Year | $147.42 | $270.61 |
| Revenue Next Year | $39.42 | $0.31 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 522.13 | 2.13 |
| 52 Week Low | $1.04 | $3.80 |
| 52 Week High | $3.68 | $6.25 |
Technical Indicators
Market Signals| Indicator | GERN | CSAN |
|---|---|---|
| Relative Strength Index (RSI) | 51.44 | 35.47 |
| Support Level | $1.30 | $3.94 |
| Resistance Level | $1.37 | $4.06 |
| Average True Range (ATR) | 0.07 | 0.15 |
| MACD | -0.01 | -0.04 |
| Stochastic Oscillator | 10.00 | 10.85 |
Price Performance
Historical ComparisonAbout GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.
About CSAN Cosan S.A. ADS
Cosan SA engages in several services throughout the energy and logistics sectors. Its reportable segments are Raizen, Compass, Moove, Rumo, and Radar. It generates the majority of its revenue from Raizen which operates in the production, commercialization, origination, and trading of ethanol, bioenergy, resale, and trading of electricity, renewable sources, marketing, origination, and trading of sugar and fuels, and lubricant.